Further research has discovered that SEs can activate the expression of “tumor-specific transcript” MARCO-TST in triple-negative breast cancer, and for the first time confirmed that BET inhibitors can be a potential treatment option for patients with triple-negative breast cancer (Yang et al., 2022). The gene discussed is TST; the disease is triple-negative breast carcinoma.